Abstract: One embodiment includes a bicycle frame that includes a plurality of square cross-section tubing members, wherein all tubing members are straight, and are consistent in cross-sectional dimensions along their length and wherein each tubing member is cut to length with a straight cut defining a tubing opening formed by an edge that extends along a single plane.

Abstract: One embodiment includes a bicycle frame that includes a plurality of square cross-section tubing members, wherein all tubing members are straight, and are consistent in cross-sectional dimensions along their length and wherein each tubing member is cut to length with a straight cut defining a tubing opening formed by an edge that extends along a single plane.

Abstract: The present invention relates to a method for treating a human patient having a proliferative disorder by administering an effective amount of a pre-treatment to the patient prior to administering an effective amount of a nucleotide-based composition that inhibits the over-expression of a target gene that causes the proliferative disorder. The present invention includes pre-treatment with one or more radiotherapy such as an X ray, a proton beam, an electron beam; hyperthermic therapy, ultrasonic therapy, chemotherapy and a biologic therapy. The invention also relates to an improved dose and scheduling sequence for treating a human patient in need thereof with such a nucleotide-based inhibitor of gene expression.

Abstract: The present invention relates to a combination of a pharmaceutical composition comprising a gallium compound, especially gallium nitrate, and one or more nonchemotherapeutic anticancer agents (NCAA) including antibodies, antisense molecules, anti-telomerase agents, aptamers, biologic response modifiers, bisphosphonates, cytotoxic fusion proteins, immunomodulatory agents, immunostimulatory agents, molecular decoys, molecular inhibitors, proteasome inhibitors, protein kinase inhibitors, retinoids, transcription factors and arsenic compounds, for the treatment of neoplasic disease in a mammal in need of treatment thereof.

Abstract: This invention relates to oligonucleotides comprising a molecular switch which may exist in an “open” or “closed” position. The molecular switch portion of the probe is particularly sensitive to the identity of sequences complementary to the molecular switch. Oligonucleotides containing a molecular switch are applicable to all kinds of hybridization processes. Due to the sensitivity of the switch domain of the oligonucleotide, probes containing a molecular switch are particularly useful in the identification of single point mismatches. More specifically, a portion, but not all, of the oligonucleotide becomes unbound from a mismatched target. The invention further relates to methods of using said oligonucleotides for research reagents, and clinical diagnostics. An exemplary oligonucleotide comprises a first hybridizable domain, a second bridging block domain, and a third binding domain.

Abstract: A new and distinct cultivar of Aconitum plant named ‘Royal Flush’, characterized by its upright plant habit; dark green-colored foliage; freely flowering habit; and dark blue-colored flowers.

Abstract: A new and distinct cultivar of Helenium plant named ‘Helbro’, characterized by its upright and somewhat outwardly spreading plant habit; freely basal branching growth habit; freely flowering habit; large upright-facing inflorescences with yellow and red bi-colored ray florets; and strong and erect peduncles that tolerate wind and rain.